A MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF THE EFFICACY AND SAFETY OF COMBINATION APREMILAST AND TOPICAL THERAPY IN SUBJECTS WITH MODERATE PLAQUE PSORIASIS WHO HAVE NOT RESPONDED ADEQUATELY TO TOPICAL TREATMENTS ALONE
Latest Information Update: 15 Jun 2022
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms PROMINENT
- Sponsors Amgen; Celgene Corporation
Most Recent Events
- 11 Jun 2022 Results published in the Dermatology and Therapy
- 25 Mar 2022 According to an Amgen media release, data will be presented at the American Academy of Dermatology (AAD) congress.
- 13 Sep 2021 According to an Amgen media release, data from the study will be presented at the European Academy of Dermatology and Venereology (EADV) 30th Congress 2021.